Literature DB >> 7511514

Color VEPs in Parkinson's disease.

L Barbato1, S Rinalduzzi, M Laurenti, S Ruggieri, N Accornero.   

Abstract

Evoked potential studies have confirmed visual pathway impairment in Parkinson's disease. Dopamine is also known to be involved in retinal color vision mechanisms. In this study, pattern evoked potentials were recorded in 20 parkinsonian patients in "on" and "off" conditions to compare the sensitivity of black-and-white and color pattern stimuli. Evoked responses to colored patterns proved more sensitive to L-DOPA therapy. This finding supports the proposed dopamine modulation of the retinal color system and suggests that color pattern evoked potential studies might be used in monitoring dopamine therapy in parkinsonian patients.

Entities:  

Mesh:

Year:  1994        PMID: 7511514     DOI: 10.1016/0168-5597(94)90057-4

Source DB:  PubMed          Journal:  Electroencephalogr Clin Neurophysiol        ISSN: 0013-4694


  13 in total

1.  Visual-evoked potentials to onset of chromatic red-green and blue-yellow gratings in Parkinson's disease never treated with L-dopa.

Authors:  F Sartucci; Vittorio Porciatti
Journal:  J Clin Neurophysiol       Date:  2006-10       Impact factor: 2.177

2.  Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease.

Authors:  T Büttner; W Kuhn; T Müller; F L Welter; J Federlein; K Heidbrink; H Przuntek
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  The effect of docosahexaenoic Acid on visual evoked potentials in a mouse model of Parkinson's disease: the role of cyclooxygenase-2 and nuclear factor kappa-B.

Authors:  Ozlem Ozsoy; Gamze Tanriover; Narin Derin; Nimet Uysal; Necdet Demir; Burcu Gemici; Ceren Kencebay; Piraye Yargicoglu; Aysel Agar; Mutay Aslan
Journal:  Neurotox Res       Date:  2011-01-14       Impact factor: 3.911

4.  Potential role of retina as a biomarker for progression of Parkinson's disease.

Authors:  Tian Tian; Xiao-Hua Zhu; Yun-Hai Liu
Journal:  Int J Ophthalmol       Date:  2011-08-18       Impact factor: 1.779

Review 5.  Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease.

Authors:  Jee-Young Lee; Antonio Martin-Bastida; Ane Murueta-Goyena; Iñigo Gabilondo; Nicolás Cuenca; Paola Piccini; Beomseok Jeon
Journal:  Nat Rev Neurol       Date:  2022-02-17       Impact factor: 44.711

6.  Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations.

Authors:  V Leuzzi; S Rinalduzzi; F Chiarotti; P Garzia; G Trasimeni; N Accornero
Journal:  J Inherit Metab Dis       Date:  1998-06       Impact factor: 4.982

7.  Visual symptoms in Parkinson's disease.

Authors:  R A Armstrong
Journal:  Parkinsons Dis       Date:  2011-05-25

Review 8.  Balance dysfunction in Parkinson's disease.

Authors:  Steno Rinalduzzi; Carlo Trompetto; Lucio Marinelli; Alessia Alibardi; Paolo Missori; Francesco Fattapposta; Francesco Pierelli; Antonio Currà
Journal:  Biomed Res Int       Date:  2015-01-14       Impact factor: 3.411

Review 9.  Oculo-Visual Dysfunction in Parkinson's Disease.

Authors:  R A Armstrong
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

10.  Severity-Dependent Effects of Parkinson's Disease on Perception of Visual and Vestibular Heading.

Authors:  Sinem Balta Beylergil; Mikkel Petersen; Palak Gupta; Mohamed Elkasaby; Camilla Kilbane; Aasef G Shaikh
Journal:  Mov Disord       Date:  2020-10-26       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.